Maria Jarecka, Piotr Borowicz

Leki inkretynowe – inkretynomimetyki i gliptyny (inhibitory DPP-IV) – nowa klasa preparatow hipoglikemizujących w cukrzycy typu 2

Incretin drugs – incretin mimetics and gliptins (DPP-IV inhibitors) – new class of hipoglycemic agents in type 2 diabetes

Type 2 diabetes is a chronic, progressive disease with a various pathophysiology. It is one of the most important diseases of our time, with reported incidence increasing every year worldwide. Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), termed “incretins”, are intestinal hormones which stimulate β-cells to secrete insulin in a glucosedependent manner. They are responsible for 50-70% of insulin secretion in healthy subjects. In type 2 diabetes the secretion of these hormones is diminished and reduction of the effect of incretins plays a role in the pathogenesis of diabetes. In recent years, the “incretin-based” therapies have been developed to influence hyperglycemia through either mimicking the action of the GLP-1 (incretin mimetics) or by inhibiting the activity of the enzyme that degrades GLP-1 (DPP-IV inhibitors). Physiological characteristics of the incretin hormones GLP-1 and GIP, modes of action of incretin mimetics and DPP-IV inhibitors, pharmacokinetic profile and therapeutic indications for these medicines are presented.
Keywords: type 2 diabetes, GLP-1, GIP, incretin defect, incretin mimetics, gliptins (DPP-IV inhibitors).